Pharma fears corruption of ‘hugely successful’ Bayh-Dole Act
Counsel at Pfizer, Novartis and Wolf Greenfield, and one of the bill’s authors, are concerned that COVID could compel parties to misuse a 40-year-old act that stimulates US innovation
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: